PARP1 and cancer: Indeed, preclinical data have revealed that BRCA1/2-mutant cancer cells are sensitive to PARP-1 inhibition due to their dependence on PARP-1 activity for DNA (base excision) repair and, subsequently, survival [43,44,45,46,47,48,49,50,51].